Navigation Links
avVaa World Health Care Products, Inc. Announces DRTV Test Results
Date:9/15/2009

LUMBY, BC, Sept. 15 /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the results of its first DRTV test week.

avVaa World Health Care Products, Inc. announced a successful first test for the Neuroskin(R) Psoriasis Relief DRTV media campaign. A total of 32 DRTV commercials were shown between August 24 and September 1, 2009, using both hard and soft sell formats. Consumer response was immediate and very high, with over 90 phone calls and 1200 website hits.

"Our call center conversion rate was strong," stated Lorie Campbell-Farley, President and COO. "Half of our callers placed an order, and 57% of those who ordered upgraded their purchase to at least 3 bottles." Call center representatives reported that approximately 5% of callers did not have a credit card, so did not purchase. In response, avVaa added check by phone services in early September.

The incredible website response made it clear that a majority of consumers prefer to purchase online. There were 1200 views of www.MyNeuroskin.com, with an average of 4 minutes being spent on the site. This indicates that a majority of viewers moved ahead to the checkout page, which is done by typing in shipping information and clicking 'Rush My Order Now. However, the website was unable to process credit card orders at the time.

"Unfortunately we were unable to capitalize on our web ordering until the end of the test week," said Mrs. Campbell-Farley. "There were significant delays from the vendor in receiving our credit card processing. We had been assured we would be up and running by August 21, but did not receive our final setup until September 1." Web ordering became available late in the day on September 1st, and orders began coming in immediately.

As a result of the test week, avVaa is looking at alternative media buying options. "Our audience reach was not satisfactory," commented Mrs. Campbell-Farley. "It is a testimonial to the strength of our Neuroskin product that it received such a strong response. We are looking at options for getting better time slots and higher saturation for the money we spend.

"We are very confident in the marketability of Neuroskin(R) Psoriasis Relief. The strong consumer response definitely justifies a second test, which we anticipate launching within the next two weeks."

Should this second test be as successful as the first one, then avVaa will at that time be confident enough to start their national media campaign shortly thereafter. "It is always best to resolve all issues in test phases, and by doing so, when all the kinks have been resolved, we will be confident that both a national infomercial campaign and internet campaign, which was announced on September 14th, 09 will jointly produce exceptional results for the Company and for all our shareholders. The next couple of months will be monumental for avVaa, and we are excited to roll out our psoriasis product to the world", concluded Mrs. Campbell-Farley.

About avVaa World Health Care Products

avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(R) line of skin care products through mass, food and drug channels in the United States and globally. The Company's secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: www.avvaa.com.

Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved.

Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.


'/>"/>
SOURCE avVaa World Health Care Products
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
3. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
4. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
5. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
6. Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention
7. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
8. Depression May Be Worlds Most Disabling Disease
9. Concentra Opens On-Site Medical Unit at World Trade Center Site
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. Womens World Banking Welcomes New Network Member From Tunisia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 and ... educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd said, ... patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to using ... Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 years, ... USA, and former member of the American Association of Christian Counselors. Rachel studied ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/22/2017)... (PRWEB) , ... April 22, ... ... Administration of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its ... Heron-Doerr, PROSHRED® Philadelphia specializes in providing information destruction , recycling, ...
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology: